Apr 27, 2017
Cynata Therapeutics is an Australian stem cell and regenerative
medicine company that is creating a therapeutic stem cell platform
technology, Cymerus™, using discoveries made at the University of
Wisconsin-Madison.
Dr Kilian Kelly, Vice President, Cynata talks about Cymerus™. A
platform for stem cell technology based upon extremely important
and versatile stem cells known as mesenchymoangioblasts (MCAs).
MCAs are a predecessor of mesenchymal stem (or stromal) cells
(MSCs) which are being examined for such diseases such as
osteoarthritis, Crohn’s disease and heart disease.
Kilian talks about utilizing iPSCs originating from an adult donor
as the preliminary material for producing MCAs and in turn for
manufacturing the MSC therapeutic product. This opens up a wide
range of therapeutic and manufacturing possibilities for the
Company.
The Cymerus™ technology has numerous features that makes it perfect
for the growth of cell-based therapeutics. This has the potential
to create a new standard in the emergent arena of regenerative
medicine and stem cell therapeutics and provides Cynata with both a
unique differentiator and an important competitive position.
Listen, subscribe and share to help our podcasting efforts.
Contribute Bitcoin to fuel our interviews and keep us going!